Ray June
@rayjune.bsky.social
Rheumatology/ Internal Medicine/ Clinical Educator in GME/ Sports Enthusiast/ Husband/ Daughter Dad.
Views are my own.
Views are my own.
Reposted by Ray June
Outstanding review.
Identification and Treatment of Alcohol Use Disorder | New England Journal of Medicine www.nejm.org/doi/full/10....
Identification and Treatment of Alcohol Use Disorder | New England Journal of Medicine www.nejm.org/doi/full/10....
Identification and Treatment of Alcohol Use Disorder | NEJM
Several clinical and biologic methods are available to identify alcohol use disorder. Pharmacologic treatment is available, but it is underused.
www.nejm.org
January 15, 2025 at 11:38 PM
Outstanding review.
Identification and Treatment of Alcohol Use Disorder | New England Journal of Medicine www.nejm.org/doi/full/10....
Identification and Treatment of Alcohol Use Disorder | New England Journal of Medicine www.nejm.org/doi/full/10....
Reposted by Ray June
Novel TYK2 inhibitor Zasocitinib
Interest in TYK2, part of the JAK family, is rising due to the success of JAK inhibitors in rheumatic disease treatment. TYK2 is vital for immune activation but has limited roles in metabolic and hematopoietic pathways.
https://buff.ly/3VdI5rV
Interest in TYK2, part of the JAK family, is rising due to the success of JAK inhibitors in rheumatic disease treatment. TYK2 is vital for immune activation but has limited roles in metabolic and hematopoietic pathways.
https://buff.ly/3VdI5rV
Novel TYK2 inhibitor Zasocitinib | RheumNow
Similar to JAKs, TYK2 is an important mediator of innate and adaptive immune activation. Unlike JAKs, however, TYK2 is thought to play a minimal role in other pathways, such as metabolic and…
buff.ly
December 2, 2024 at 8:00 PM
Novel TYK2 inhibitor Zasocitinib
Interest in TYK2, part of the JAK family, is rising due to the success of JAK inhibitors in rheumatic disease treatment. TYK2 is vital for immune activation but has limited roles in metabolic and hematopoietic pathways.
https://buff.ly/3VdI5rV
Interest in TYK2, part of the JAK family, is rising due to the success of JAK inhibitors in rheumatic disease treatment. TYK2 is vital for immune activation but has limited roles in metabolic and hematopoietic pathways.
https://buff.ly/3VdI5rV
Reposted by Ray June
Hello, #MedSky community! We’re excited to begin our Bluesky journey.
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
December 6, 2024 at 8:24 PM
Hello, #MedSky community! We’re excited to begin our Bluesky journey.
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
Reposted by Ray June
Axial spondyloarthritis: a review in @jama.com by oomf (Mohamad Bittar)
Thanks for sharing @ruthjeannapier.bsky.social @restovall.bsky.social
pubmed.ncbi.nlm.nih.gov/39630439/
Thanks for sharing @ruthjeannapier.bsky.social @restovall.bsky.social
pubmed.ncbi.nlm.nih.gov/39630439/
December 4, 2024 at 10:57 PM
Axial spondyloarthritis: a review in @jama.com by oomf (Mohamad Bittar)
Thanks for sharing @ruthjeannapier.bsky.social @restovall.bsky.social
pubmed.ncbi.nlm.nih.gov/39630439/
Thanks for sharing @ruthjeannapier.bsky.social @restovall.bsky.social
pubmed.ncbi.nlm.nih.gov/39630439/
Reposted by Ray June
2024 Lasker-DeBakey Clinical Medical Research Award winner
Lotte Bjerre Knudsen describes her discovery of glucagon-like peptide-1 for the development of therapies to treat patients with obesity.
ja.ma/3ZqH7ep
Lotte Bjerre Knudsen describes her discovery of glucagon-like peptide-1 for the development of therapies to treat patients with obesity.
ja.ma/3ZqH7ep
December 1, 2024 at 3:53 PM
2024 Lasker-DeBakey Clinical Medical Research Award winner
Lotte Bjerre Knudsen describes her discovery of glucagon-like peptide-1 for the development of therapies to treat patients with obesity.
ja.ma/3ZqH7ep
Lotte Bjerre Knudsen describes her discovery of glucagon-like peptide-1 for the development of therapies to treat patients with obesity.
ja.ma/3ZqH7ep
Reposted by Ray June
Immunology for the Rheumatologist: Arthritis & Rheumatology Introduces a New Problem-Based Immunology Review Series With Great Educational Potential - PubMed https://buff.ly/4hZt0nN I learned A&R started this immunology series.
November 24, 2024 at 2:53 PM
Immunology for the Rheumatologist: Arthritis & Rheumatology Introduces a New Problem-Based Immunology Review Series With Great Educational Potential - PubMed https://buff.ly/4hZt0nN I learned A&R started this immunology series.
Reposted by Ray June
The obvious choice for our next CDC director
November 22, 2024 at 3:30 AM
The obvious choice for our next CDC director
Reposted by Ray June
🆕 #ACR24 | Updated Guidelines for Lupus Nephritis Treatment & Management 🫘
Highlights 🔶
• Critical role of renal biopsy
• Differences for treatment by LN Class
• Adjunctive Rx w/ HCQ & RAASi
• GC pulse ⇢ *moderate/low* dose PDN
#Lupus #NephSky #RheumSky #Rheumatology #MedSky
Highlights 🔶
• Critical role of renal biopsy
• Differences for treatment by LN Class
• Adjunctive Rx w/ HCQ & RAASi
• GC pulse ⇢ *moderate/low* dose PDN
#Lupus #NephSky #RheumSky #Rheumatology #MedSky
November 18, 2024 at 11:37 PM
Reposted by Ray June
The Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute (RPI) launched the joint Center for Engineering and Precision Medicine (CEPM). Applications are now open for our inaugural PhD in Health Science Engineering. Apply by January 1, 2025! cepmresearch.org/academic-pro...
Academic Programs - Center for Engineering and Precision Medicine
cepmresearch.org
November 21, 2024 at 3:16 AM
The Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute (RPI) launched the joint Center for Engineering and Precision Medicine (CEPM). Applications are now open for our inaugural PhD in Health Science Engineering. Apply by January 1, 2025! cepmresearch.org/academic-pro...